NEW YORK (GenomeWeb News) – Celera said today that the University of California, San Francisco has licensed the rights to use Celera’s KIF6 gene-related intellectual property to develop an in-house test for cardiovascular risk and statin benefit.

The agreement makes UCSF the first lab in the US besides Celera’s Berkeley HeartLab subsidiary to use the Celera discoveries.

Studies have shown an association between KIF6, which encodes a kinesin-like protein 6, and cardiovascular risk and statin benefit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.